Join
Live feed
·
PRReleasevia Quantisnow
Chinook Therapeutics Inc. logo

Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022

ByQuantisnow·Wall Street's wire, on your screen.
KDNY· Chinook Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KDNY (Chinook Therapeutics Inc.) and more on Quantisnow.